|
Conference on Biomarkers 2012 To be held on 26th Sept 2012 at London Marriott Marble Arch Hotel, London, UK CONFERENCE INTRODUCTION:- GLOBAL MARKET FOR BIOMARKERS TO BE WORTH $33.3 BILLION IN 2015 According to a new technical market research report, the value of the global market for biomarkers was nearly $13.5 billion in 2010, but is expected to increase to nearly $33.3 billion in 2015, for a five-year compound annual growth rate (CAGR) of 19.8%. The largest segment of the market, genomics, is projected to increase at a CAGR of 26.9% to nearly $17 billion in 2015, after being valued at an estimated $5.1 billion in 2010. The second-largest segment, imaging, is estimated at $4.2 billion in 2010, but is expected to increase at a CAGR of 14.8% to $8.4 billion in 2015. The proteomics segment will increase in value from $1.8 billion in 2010 to nearly $3.5 billion in 2015, for a CAGR of 13.5%. The bioinformatics segment will increase at a CAGR of 19.3%, rising from $1.1 billion in 2010 to $2.6 billion in 2015. Swot Analysis The biomarkers market presents the largest of all opportunities in representative disease subsegments. This study investigates one of the most important market drivers: The introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period. Applications for biomarkers are wide-ranging, and will have a pivotal impact in medicine. Targeted therapies, improved patient selection for clinical trial criteria, early drug rationalization, and proactively identifying adverse events for patients are some of the leading applications for biomarkers currently and through the forecast period. Biomarker professionals will gather together to answer the all-important question- how can we get biomarkers to add value? How do you develop new medicines, which demonstrate real value through predictable outcomes in targeted patient groups? The event is a one day strategic conference tackling these questions and providing participants with a thorough review of the use of biomarkers, their effectiveness and their potential to transform R & D. It gives us immense pleasure in welcoming you to “Biomarkers 2012 - Successful Strategies & Developments in Biomarkers”. KEY SPEAKERS:- Mark Broenstrup, Director Biomarkers & Diagnostics, Sanofi-Aventis Joachim Reischl, Head Global Biomarker Strategy and Development, Bayer Pharma Jochen Theis, Owner & Principal Consultant, InHeCon (Germany) – Former Global Head, Biomarkers, F. Hoffmann-La Roche David W. Moskowitz, Chairman, CEO & CMO, GenoMed (USA) John Lambert, Vice President and Chief Medical Officer Clinical Pharmacology, Parexel Sylvie Le Glédic, Director, Voisin Consulting Life Sciences Mohamed Oubihi, EU Regulatory Intelligence Lead, International Regulatory Affairs, Biogen Idec Malcolm I Mitchell, Senior Medical Fellow, Clinical Pharmacology, Eli Lilly Austin Tanney, Scientific Liaison Manager, Almac Diagnostics Eugenii (Ilan) A. Rabiner, Head, Imaging Applications & CMO, Imanova Lincoln Tsang, Partner, Arnold & Porter LLP Maria Hernandez Fuentes, Senior Lecturer in Translational Research, L.O.R.D. lab. MRC Centre for Transplantation, King's College London For more information kindly visit : http://www.companyprofilesandconferences.com/seminars-conferences/Biomarkers-2012.html Or Contact us at : Company Profiles And Conferences Phone : + 91 22 27812707 Fax : + 91 22 27812290 E-mail : info@companyprofilesandconferences.com Website : www.companyprofilesandconferences.com
Related Articles -
Biomarkers, Pharma, health, conference,
|
